Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies

Abstract The need for high-affinity, SARS-CoV-2-specific monoclonal antibodies (mAbs) is critical in the face of the global COVID-19 pandemic, as such reagents can have important diagnostic, research, and therapeutic applications. Of greatest interest is the ~ 300 amino acid receptor binding domain...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Asheley P. Chapman, Xiaoling Tang, Joo R. Lee, Asiya Chida, Kristina Mercer, Rebekah E. Wharton, Markus Kainulainen, Jennifer L. Harcourt, Roosecelis B. Martines, Michelle Schroeder, Liangjun Zhao, Anton Bryksin, Bin Zhou, Eric Bergeron, Brigid C. Bollweg, Azaibi Tamin, Natalie Thornburg, David E. Wentworth, David Petway, Dennis A. Bagarozzi, M. G. Finn, Jason M. Goldstein
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/62c76690f37c478981f0b0dd9033fece
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:62c76690f37c478981f0b0dd9033fece
record_format	dspace
spelling	oai:doaj.org-article:62c76690f37c478981f0b0dd9033fece2021-12-02T14:29:09ZRapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies10.1038/s41598-021-88809-02045-2322https://doaj.org/article/62c76690f37c478981f0b0dd9033fece2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88809-0https://doaj.org/toc/2045-2322Abstract The need for high-affinity, SARS-CoV-2-specific monoclonal antibodies (mAbs) is critical in the face of the global COVID-19 pandemic, as such reagents can have important diagnostic, research, and therapeutic applications. Of greatest interest is the ~ 300 amino acid receptor binding domain (RBD) within the S1 subunit of the spike protein because of its key interaction with the human angiotensin converting enzyme 2 (hACE2) receptor present on many cell types, especially lung epithelial cells. We report here the development and functional characterization of 29 nM-affinity mouse SARS-CoV-2 mAbs created by an accelerated immunization and hybridoma screening process. Differing functions, including binding of diverse protein epitopes, viral neutralization, impact on RBD-hACE2 binding, and immunohistochemical staining of infected lung tissue, were correlated with variable gene usage and sequence.Asheley P. ChapmanXiaoling TangJoo R. LeeAsiya ChidaKristina MercerRebekah E. WhartonMarkus KainulainenJennifer L. HarcourtRoosecelis B. MartinesMichelle SchroederLiangjun ZhaoAnton BryksinBin ZhouEric BergeronBrigid C. BollwegAzaibi TaminNatalie ThornburgDavid E. WentworthDavid PetwayDennis A. BagarozziM. G. FinnJason M. GoldsteinNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Asheley P. Chapman Xiaoling Tang Joo R. Lee Asiya Chida Kristina Mercer Rebekah E. Wharton Markus Kainulainen Jennifer L. Harcourt Roosecelis B. Martines Michelle Schroeder Liangjun Zhao Anton Bryksin Bin Zhou Eric Bergeron Brigid C. Bollweg Azaibi Tamin Natalie Thornburg David E. Wentworth David Petway Dennis A. Bagarozzi M. G. Finn Jason M. Goldstein Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies
description	Abstract The need for high-affinity, SARS-CoV-2-specific monoclonal antibodies (mAbs) is critical in the face of the global COVID-19 pandemic, as such reagents can have important diagnostic, research, and therapeutic applications. Of greatest interest is the ~ 300 amino acid receptor binding domain (RBD) within the S1 subunit of the spike protein because of its key interaction with the human angiotensin converting enzyme 2 (hACE2) receptor present on many cell types, especially lung epithelial cells. We report here the development and functional characterization of 29 nM-affinity mouse SARS-CoV-2 mAbs created by an accelerated immunization and hybridoma screening process. Differing functions, including binding of diverse protein epitopes, viral neutralization, impact on RBD-hACE2 binding, and immunohistochemical staining of infected lung tissue, were correlated with variable gene usage and sequence.
format	article
author	Asheley P. Chapman Xiaoling Tang Joo R. Lee Asiya Chida Kristina Mercer Rebekah E. Wharton Markus Kainulainen Jennifer L. Harcourt Roosecelis B. Martines Michelle Schroeder Liangjun Zhao Anton Bryksin Bin Zhou Eric Bergeron Brigid C. Bollweg Azaibi Tamin Natalie Thornburg David E. Wentworth David Petway Dennis A. Bagarozzi M. G. Finn Jason M. Goldstein
author_facet	Asheley P. Chapman Xiaoling Tang Joo R. Lee Asiya Chida Kristina Mercer Rebekah E. Wharton Markus Kainulainen Jennifer L. Harcourt Roosecelis B. Martines Michelle Schroeder Liangjun Zhao Anton Bryksin Bin Zhou Eric Bergeron Brigid C. Bollweg Azaibi Tamin Natalie Thornburg David E. Wentworth David Petway Dennis A. Bagarozzi M. G. Finn Jason M. Goldstein
author_sort	Asheley P. Chapman
title	Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies
title_short	Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies
title_full	Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies
title_fullStr	Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies
title_full_unstemmed	Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies
title_sort	rapid development of neutralizing and diagnostic sars-cov-2 mouse monoclonal antibodies
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/62c76690f37c478981f0b0dd9033fece
work_keys_str_mv	AT asheleypchapman rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT xiaolingtang rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT joorlee rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT asiyachida rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT kristinamercer rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT rebekahewharton rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT markuskainulainen rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT jenniferlharcourt rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT roosecelisbmartines rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT michelleschroeder rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT liangjunzhao rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT antonbryksin rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT binzhou rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT ericbergeron rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT brigidcbollweg rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT azaibitamin rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT nataliethornburg rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT davidewentworth rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT davidpetway rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT dennisabagarozzi rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT mgfinn rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies AT jasonmgoldstein rapiddevelopmentofneutralizinganddiagnosticsarscov2mousemonoclonalantibodies
_version_	1718391255720787968

Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies

Ejemplares similares